Megan Garlapow, PhD

All articles by Megan Garlapow, PhD

• Case report: Identifying rare Rh blood types can prevent newborn anemia

  The report highlights how anti-Rh17 antibodies in mothers with a rare Rh phenotype can cause HDFN, leading to severe anemia and jaundice.

• Early diagnosis of fetal anemia improves outcomes for infants

  HDFN is a common cause of fetal anemia in infants, and it can lead to serious complications if not treated early.

• Severe case of HDFN caused by anti-Fya alloantibodies

  Anti-Fya antibodies can cause severe HDFN, underscoring the need for broader prenatal screening, authors of a recent study wrote.

• Improved testing protocols could protect newborns from severe HDFN

  Wider use of anti-D prophylaxis and better prenatal care could reduce the severe health risks newborns face from HDFN, a study found.

• Case report: Minor blood group incompatibility led to severe HDFN

  A minor blood group incompatibility with anti-c caused severe hemolytic disease of the fetus and newborn even without ABO or Rh(D) mismatch.

• Case report: Newborn with FNAIT and HDFN successfully treated

  A newborn survived a rare combination of Jka hemolytic disease and HDFN thanks to early diagnosis and aggressive treatment.

• Newborn with severe HDFN may have benefited from early testing

  Hemolytic disease of the fetus and newborn (HDFN) can occur in RhD-positive mothers due to antibodies such as anti-Jkb.

• Case study: Blocked D phenomenon can make HDFN diagnosis challenging

  Rh incompatibility can cause hemolytic disease of the fetus and newborn, even when newborn blood typing appears normal.

• Review: Nipocalimab shows promise in preventing HDFN

  Early detection and treatment reduce fetal death and severe anemia, and nipocalimab can help detect HDFN earlier and prevent it from occurring.

• Cord blood potentially safe for transfusions in newborns with HDFN

  Umbilical cord blood (UCB) may offer a safe transfusion source for treating hemolytic disease of the fetus and newborn (HDFN).